PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose
20 9월 2023 - 9:00PM
PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT
BioRobotics”), a surgical robotics company focused on developing
transformative solutions in urology, proudly announces the grand
opening of its state-of-the-art global corporate headquarters in
San Jose, California. This expansive facility will accommodate the
company's plans for continued growth.
PROCEPT manufactures the AquaBeam Robotic System, an
image-guided, automated surgical robotic system dedicated to the
treatment of benign prostatic hyperplasia (BPH). San Jose was
selected to attract top talent and provide employees with
unparalleled resources, enabling them to drive our mission of
innovation in surgical robotics and maintaining the highest
standards in manufacturing processes.
Reza Zadno, CEO of PROCEPT BioRobotics, remarked, “Our success,
demonstrated by the robust demand for Aquablation® therapy, has
accelerated this exciting move. One of the driving factors behind
the selection of San Jose as the ideal location for our new global
headquarters was the rich pool of talent available in the heart of
silicon valley. With a diverse talent pool spanning various roles
and skillsets, we are well-positioned to foster collaboration,
nurture talent, and cultivate the next generation of surgical
robotics innovators.”
“We’re thrilled to welcome PROCEPT BioRobotics to San José,”
said Mayor Matt Mahan. “As the Capital of Silicon Valley, our city
has long been synonymous with innovation – with a rich history of
entrepreneurship and unparalleled access to talent, it's no secret
why we’re the go-to destination for industry leaders.”
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 150 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Important Safety InformationAll surgical
treatments have inherent and associated side effects. For a list of
potential side effects
visit https://aquablation.com/safety-information/.
Investor Contact:Matt BacsoVP, Investor
Relations and Business
Operationsm.bacso@procept-biorobotics.com
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9f4eb6fe-cec8-466e-9957-d5fd006a8076
https://www.globenewswire.com/NewsRoom/AttachmentNg/2c1b5dd3-69d2-4cf1-bcaa-f294388e6928
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024